EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #04437_C
含重组细胞因子的甲基纤维素培养基，用于快速进行人造血细胞集落测定
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
MethoCult™Express用于人脐带血（CB）样本的造血集落形成单位（CFU）检测，最低培养期为7天。适用于去除红细胞的脐带血样本，冻存复苏后的全脐带血样本，以及脐带血单个核细胞（CB-MNC）样本。MethoCult™Express对人造血祖细胞的生长和计数进行了优化，所需时间比标准CFU检测的14 -16天短得多。在MethoCult™Express中，在培养7天后即可计数包含至少20个细胞的集落。此时，大多数集落是不成熟的，尚未分化成形态上可区分的集落类型。因此7天时的集落数量主要反映样本中造血祖细胞的总频率，而不区分不同类型的祖细胞。
如果将培养时间延长到14 - 16天，可以计数来自不同祖细胞的集落，包括：红系祖细胞形成的BFU-E集落、粒细胞-巨噬细胞系祖细胞形成的CFU-G、CFU-M、CFU-GM集落、多潜能祖细胞形成的CFU-GEMM集落。
浏览我们关于CFU分析的常见问题解答（FAQs），并探索其作为细胞治疗工作流程中的应用价值。
包含
• 含甲基纤维素的Iscove's MDM
• 胎牛血清
• 牛血清白蛋白
• 细胞因子，包括促红细胞生成素 (EPO)
• 添加物
分类
半固体培养基，专用培养基
细胞类型
造血干/祖细胞
种属
人
应用
细胞培养，克隆筛选，功能学筛选
品牌
MethoCult
研究领域
脐带血库，药物发现和毒性检测，干细胞生物学，移植研究
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (13)
常见问题
文献 (14)
Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity.
Blood 2000 OCT
Abstract
There is evidence that the total cellular content of placental cord blood (PCB) grafts is related to the speed of engraftment,though the total nucleated cell (TNC) dose is not a precise predictor of the time of neutrophil or platelet engraftment. It is important to understand the reasons for the quantitative association and to improve the criteria for selecting PCB grafts by using indices more precisely predictive of engraftment. The posttransplant course of 204 patients who received grafts evaluated for hematopoietic colony-forming cell (CFC) content among 562 patients reported previously were analyzed using univariate and multivariate life-table techniques to determine whether CFC doses predicted hematopoietic engraftment speed and risk for transplant-related events more accurately than the TNC dose. Actuarial times to neutrophil and platelet engraftment were shown to correlate with the cell dose,whether estimated as TNC or CFC per kilogram of recipient's weight. CFC association with the day of recovery of 500 neutrophils/microL,measured as the coefficient of correlation,was stronger than that of the TNC (R = -0.46 and -0.413,respectively). In multivariate tests of speed of platelet and neutrophil engraftment and of probability of posttransplantation events,the inclusion of CFC in the model displaced the significance of the high relative risks associated with TNC. The CFC content of PCB units is associated more rigorously with the major covariates of posttransplantation survival than is the TNC and is,therefore,a better index of the hematopoietic content of PCB grafts. (Blood. 2000;96:2717-2722)
Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation.
Bone marrow transplantation 2004 JUN
Abstract
From July 1995 to December 2001,42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated,textless or = 2 antigen HLA mismatched donors. In all,26 patients were in textless or = 2nd complete remission and 16 in more advanced phase. Conditioning regimens,graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90% (95% CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9% (95% CI: 0.04-0.24) and 35% (95% CI: 0.21-0.60),respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28% (95% CI: 0.17-0.47) and 25% (95% CI: 0.14-0.45),respectively. The 4-year overall survival (OS),leukemia-free survival (LFS) and event-free survival (EFS) were 45% (95% CI: 0.27-0.63),47% (95% CI: 0.30-0.64) and 46% (95% CI: 0.30-0.62),respectively. In multivariate analysis,the most important factor affecting outcomes was the CFU-GM dose,associated with CMV serology (P=0.003 and 0.04,respectively) in influencing OS and with patient sex (P=0.008 and 0.03,respectively) in influencing LFS. Finally,CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion,the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.
Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment.
Bone marrow transplantation 2005 MAY
Abstract
In all,78 peripheral hematopoietic progenitor cell collections from 52 patients were evaluated using our previously published validated post-thaw assays at the time of collection and following transplantation by assessment of viable CD34(+) cells,and granulocyte-macrophage colony-forming units (CFU-GM) cryopreserved in quality control vials. The median (range) post-thaw recovery of viable CD34(+) cells and CFU-GM was 66.4% (36.1-93.6%) and 63.0% (28.6-85.7%),respectively,which did not show significant correlation with the engraftment of either neutrophils (P=0.136 and 0.417,respectively) or platelets (P=0.88 and 0.126,respectively). However,the reinfused viable CD34(+) cells/kg of patient weight pre- or post-cryopreservation showed significant correlation to engraftment of neutrophils (P=0.0001 and 0.001,respectively) and platelets (P=0.023 and 0.010,respectively),whereas CFU-GM pre- or post-cryopreservation was significantly correlated to neutrophils (P=0.011 and 0.007,respectively) but not to platelets (P=0.112 and 0.100,respectively). The results show that post-cryopreservation assessment of viable CD34(+) cells or CFU-GM is as reliable a predictor of rapid engraftment as that of pre-cryopreservation measures. Therefore,the post-cryopreservation number of viable CD34(+) cells or CFU-GM should be used to eliminate the risks of unforeseen cell loss that could occur during cryopreservation or long-term storage.
更多信息
| 物种 | 人 |
|---|---|
| Contains | • Methylcellulose in Iscove's MDM • Fetal bovine serum • Bovine serum albumin • Cytokines, including erythropoietin (EPO) • Supplements |
相关产品
-
HetaSep™新鲜血液样本中去除红细胞并分离有核细胞
-
STEMvision™用于造血集落形成单位（CFU）测定的自动化和标准化集落计数
沪公网安备31010102008431号
在线联系